CN105903068A - Medical composite chitosan gel containing analgesic drug - Google Patents
Medical composite chitosan gel containing analgesic drug Download PDFInfo
- Publication number
- CN105903068A CN105903068A CN201610390055.7A CN201610390055A CN105903068A CN 105903068 A CN105903068 A CN 105903068A CN 201610390055 A CN201610390055 A CN 201610390055A CN 105903068 A CN105903068 A CN 105903068A
- Authority
- CN
- China
- Prior art keywords
- chitosan
- gel
- analgesic
- acid
- medical recombination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0023—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/0066—Medicaments; Biocides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/204—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials with nitrogen-containing functional groups, e.g. aminoxides, nitriles, guanidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/402—Anaestetics, analgesics, e.g. lidocaine
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Materials For Medical Uses (AREA)
Abstract
The invention discloses medical composite chitosan gel containing analgesic drug. The medical composite chitosan gel is prepared from, by weight, 0.5-10 parts of chitosan high molecular materials, 0.5-7 parts of analgesic drug, 0-10 parts of thickening agent, 1-25 parts of moistening agent and 48-98 parts of purified water. The medical composite chitosan gel containing the analgesic drug can effectively keep the wet environment for a wound and relieve wound pain; according to the dressing, the chitosan high molecular materials are used as a matrix, the analgesic drug is adopted in an assisted mode, the advantages of moisture absorption, moisturizing, bacteriostasis, hemostasis and the like and the effect of analgesia of the analgesic drug are combined, and the gel with excellent performance is prepared.
Description
Technical field
The present invention relates to the technical field of wound dressing, more particularly, relate to a kind of medical recombination chitosan gel containing analgesic.
Background technology
The skin of human body and mucosa are the barriers maintaining human internal environment stable and stoping microorganism to invade, the skin caused due to reasons such as ulcer, wound, burn and inflammation and mucosa injury, the a series of problem of body can be caused, such as antibacterial infects, metabolism aggravation, moisture and protein excessively runs off, endocrine and immune system dysfunction etc., serious possible threat to life.Suitable dressing should be selected when skin and mucosa injury to cover on wound, and it can play holding wound moist environment, absorption secretions, eases pain and control hemorrhage effect, thus promotes wound healing.
The use of dressing is the important means maintaining the good healing environment of wound.Traditional dressing mainly plays isolation and bacteriostasis for wound, but frequently results in wound and be dried, destroy the somatomedin of health and easily stick on cambium, can cause the secondary insult of wound when dressing is removed.Along with people's living standard and the raising of medical level, people have higher requirement for dressing:
(1) can control and absorb exudate, keep wound moist and without the environment of transudate；
(2) bacteria preventers can be provided, build the good environment of an applicable tissue growth, promote tissue growth；
(3) there is the suitable transmitance of gas and steam；
(4) easy to use, adhesion is suitable, does not cause secondary injury；
(5) nontoxic, harmless, non-stimulated.
A kind of high-quality dressing that disclosure satisfy that requirements above of gel dressing, it is therefore necessary to provide a kind of and meet above-mentioned requirements and there is the gel dressing improving performance.
Summary of the invention
In order to solve the various problems that dressing in prior art exists, it is an object of the invention to provide and a kind of there is pain relieving, stop blooding, Moist healing environment, autolyzed debridement, control scar hyperplasia and the medical recombination chitosan gel containing analgesic of physical isolation effect are provided.
The invention provides a kind of medical recombination chitosan gel containing analgesic, in parts by weight, described medical recombination chitosan gel includes following components: 0.5～10 part of chitosan family macromolecule material, 0.5～7 part of analgesic, 0～10 part of thickening agent, 1～25 part of wetting agent and 48～98 parts of purified water.
Contain an embodiment of the medical recombination chitosan gel of analgesic according to the present invention, described medical recombination chitosan gel includes following components: 1.5～6 parts of chitosan family macromolecule materials, 1～5 part of analgesic, 0～5 part of thickening agent, 4～15 parts of wetting agents and 69～93.5 parts of purified water.
An embodiment of the medical recombination chitosan gel of analgesic is contained according to the present invention, described medical recombination chitosan gel also includes pH adjusting agent, wherein, the usage amount of described pH adjusting agent is that the pH value that can adjust described medical recombination chitosan gel is to 2～11.
An embodiment of the medical recombination chitosan gel of analgesic is contained, at least one in the derivant of chitosan, the salt of chitosan and chitosan of described chitosan family macromolecule material according to the present invention；At least one in carboxymethyl chitosan, isobutyl-chitosan, hydroxypropyl chitosan and hyaluronic acid-like chitosan of the derivant of described chitosan；At least one in chitosan quaternary ammonium salt, chitosan hydrochlorate, chitosan lactate, chitosan acetate, chitosan tartarate, Chitosan Sulfate, glutamate, Chitosan citrate., chitosan succinate and chitosan acetylsalicylate of the salt of described chitosan；The molecular weight of described chitosan family macromolecule material is 1000～1000000；Preferably, the molecular weight of described chitosan family macromolecule material is 3000～500000.
An embodiment of the medical recombination chitosan gel of analgesic is contained according to the present invention, described analgesic is dispersed or dissolved in described medical recombination chitosan gel, wherein, at least one during described analgesic is selected from lignocaine or its salt, prilocaine or its salt, bupivacaine or its salt and ropivacaine or its salt.
An embodiment of the medical recombination chitosan gel of analgesic is contained, at least one in starch, alginic acid and salt, arabic gum, tragakanta, agar, cellulose, sodium carboxymethyl cellulose, hydroxypropyl cellulose, hypromellose, hydroxyethyl cellulose, methylcellulose, carbomer, gelatin, xanthan gum, hyaluronic acid, modified starch, sodium polyacrylate, polyvinyl alcohol, Polyethylene Glycol and polyvidone of described thickening agent according to the present invention.
An embodiment of the medical recombination chitosan gel of analgesic is contained, at least one in glycerol, propylene glycol, mannitol, butanediol and sorbitol of described wetting agent according to the present invention.
An embodiment of the medical recombination chitosan gel of analgesic is contained according to the present invention, described pH adjusting agent is acid or alkali, wherein, at least one in hydrochloric acid, acetic acid, sulphuric acid, boric acid, lactic acid, citric acid, tartaric acid, acetic acid and malic acid of acid, at least one in sodium hydroxide, sodium carbonate, sodium citrate and triethanolamine of alkali.
Contain an embodiment of the medical recombination chitosan gel of analgesic according to the present invention, the type of service of described medical recombination chitosan gel is amorphous gel, lamellar gel or spray form gel；It is preferably amorphous gel.
Contain an embodiment of the medical recombination chitosan gel of analgesic according to the present invention, described medical recombination chitosan gel is applicable to acute otch and has the pain chronic wound of low moderate transudate.
Compared with prior art, the medical recombination chitosan gel containing analgesic of the present invention can effectively keep the moist environment of wound and alleviate wound pain, this dressing is with chitosan family macromolecule material as substrate, it is aided with analgesic, combine the advantages such as chitosan family macromolecule material moisture absorption, moisturizing, antibacterial, hemostasis and the effect of analgesic analgesic, be prepared for the gel of a kind of function admirable.
Detailed description of the invention
All features disclosed in this specification, or disclosed all methods or during step, in addition to mutually exclusive feature and/or step, all can combine by any way.
Any feature disclosed in this specification, unless specifically stated otherwise, all can be by other equivalences or there is the alternative features of similar purpose replaced.I.e., unless specifically stated otherwise, an example during each feature is a series of equivalence or similar characteristics.
Below the medical recombination chitosan gel that the present invention contains analgesic is described in detail.
Exemplary embodiment according to the present invention, in parts by weight, above-mentioned medical recombination chitosan gel includes following components: 0.5～10 part of chitosan family macromolecule material, 0.5～7 part of analgesic, 0～10 part of thickening agent, 1～25 part of wetting agent and 48～98 parts of purified water.
Wherein, at least one in the derivant of chitosan, the salt of chitosan and chitosan of above-mentioned chitosan family macromolecule material.In the present invention, for different chitosan family macromolecule materials, can add as required or be added without thickening agent.
Preferably, described medical recombination chitosan gel includes following components: 1.5～6 parts of chitosan family macromolecule materials, 1～5 part of analgesic, 0～5 part of thickening agent, 4～15 parts of wetting agents and 69～93.5 parts of purified water.
Specifically at least one in carboxymethyl chitosan, isobutyl-chitosan, hydroxypropyl chitosan and hyaluronic acid-like chitosan of the derivant of chitosan；At least one in chitosan quaternary ammonium salt, chitosan hydrochlorate, chitosan lactate, chitosan acetate, chitosan tartarate, Chitosan Sulfate, glutamate, Chitosan citrate., chitosan succinate and chitosan acetylsalicylate of the salt of chitosan.Further, the molecular weight of above-mentioned chitosan family macromolecule material is 1000～1000000, preferably 3000～500000.
In fact, the medical recombination chitosan gel of the present invention is a kind of gel dressing and is a kind of polymer, wherein water content is 80～90%, be translucent shape and without stickiness, there is powerful slough hydratability and can effectively play autolyzed debridement effect, its high cohesion performance goes for the wound at any position, is primarily adapted for use in and is dried incrustation or has the wound of the tissue that rots；Presenting black or yellow slough for wound bed and wound that sepage is dried less, it can dissolve softening slough, reach autologous debridement effect；Can be used for the clean wound of a small amount of sepage, apply also for filling hole, chamber and sinus tract wound.The many uses of gel dressing are nontoxic, the natural macromolecular material of no antigen, good biocompatibility, biodegradable is prepared from, such as: Chitosan-phospholipid complex, collagen protein, gelatin, cellulose, alginate etc..Wherein Chitosan-phospholipid complex shows multiple advantage as gel dressing, it not only has the good advantage keeping wound moist environment, also there is the multiple function being beneficial to wound healing, such as: keep wound moist environment, promote healing, hemostasis, antibacterial, suppression cicatrix generation etc..In addition, chitosan be find up to now uniquely there is alkalescence, natural polysaccharide with positive charge, it is widely present in the carapace of shrimp, Eriocheir sinensis, insecticide etc., resource is the abundantest, it it is the second largest natural biological organic resource being only second to cellulose in nature, source reduces the price of its raw material widely, and then reduces patient medical cost, is a kind of wound dressing base material being worthy to be popularized.
At present, U.S.'s pain association Health Care Policy and research center are classified as pain as the 5th vital sign after body temperature, pulse, blood pressure, breathing.Pain can cause a series of neuroendocrine stress of body: (1) pain may result in immunoglobulin and declines, and affects wound healing speed.(2) the exception release of induced pain inflammatory mediator can make wound ischemia, anoxia, edema, can make again hormone in vivo, enzyme system Developmental and Metabolic Disorder.Protein synthesis is slow.Tissue breakdown is strengthened, unfavorable to wound healing.(3) in blood, catecholamine raises, and blood pressure raises, and causes tachycardia, arrhythmia, the shallow speed of breathing, the symptom such as Nausea and vomiting, perspiration occurs.Additionally, also have numerous studies evidence to demonstrate wound pain also can cause the anxiety of patient, anxiety level is the highest, and pain is the most serious.The pain level of anxiety and depressed wound patient of also occurring together raises, it might even be possible to increase the weight of the neuropathic pain of diabetics.Substantial amounts of research evidence display pain produces harmful effect to wound healing, so, wound pain is more and more concerned in treatment of wounds.
But simple Chitosan-phospholipid complex tends not to reach effective analgesic purpose.In order to adapt to patient's pursuit for analgesic activity, the present invention creatively add in chitosan gel rubber dressing have obvious pain relieving, analgesic activity analgesic to realize this purpose.
According to the present invention, this analgesic is dispersed or dissolved in realize analgesic effect simultaneously in medical recombination chitosan gel, and makes up the chitosan gel rubber deficiency at ease pain.Wherein, analgesic is dispersed or dissolved in described medical recombination chitosan gel, and analgesic is selected from least one in lignocaine or its salt, prilocaine or its salt, bupivacaine or its salt and ropivacaine or its salt., preferably lignocaine or its salt.
Lignocaine and salt thereof have a clear superiority for the pain relieving of wound and surgical wound: (1) lignocaine rapid-action (2～5min), effect is strong and has stronger penetration capacity；(2) lignocaine is to organizing almost without zest, and untoward reaction is relatively small, and vasodilation will not be caused to cause severe loss of blood；(3) research shows, after topical application lignocaine, blood drug level is less than poisoning concentration (> 5mg/L) decades of times, safety is high；(4) 1%～3% lignocaine can suppress a large amount of antibacterials and the growth of fungus under varying environment；(5) lignocaine has powerful antiinflammatory action；(6) lignocaine is high temperature resistant and economical and practical.Therefore, lignocaine or its salt are applied in dressing safely, effectively, and dressing analgesic effect can be given, improve the suitability of dressing.
Prilocaine local anesthetic action is similar with lignocaine, but action time is longer, and toxicity is relatively low, accumulative the least.Bupivacaine or its salt, ropivacaine or its salt are all novel long-acting amide-type local anesthetics, have anesthesia duration long, and toxicity is low, to features such as nervus motorius retarding degree are light, thus are widely used in various operation and Postoperative Analgesia After.Apply bupivacaine or its salt, ropivacaine or its salt can significantly reduce the pain in patient's agglutination, the inflammation of suppression wound location and stress in the wound surface such as burn.
In sum, the analgesics such as lignocaine or its salt have prominent advantage for wound analgesia, therefore analgesic is joined in chitosan gel rubber by the present invention, while being intended to play chitosan family macromolecule material offer Moist healing environment, autolyzed debridement, the suppression effect such as scar hyperplasia, physical isolation, increase further the effect of dressing analgesic, provide one to ease pain more efficiently gel dressing for patient.
After above two key component, the medical recombination chitosan gel of the present invention also includes multiple auxiliary materials, such as thickening agent, wetting agent etc..
Wherein, thickening agent can be selected from least one in starch, alginic acid and salt thereof, arabic gum, tragakanta, agar, cellulose, sodium carboxymethyl cellulose, hydroxypropyl cellulose, hypromellose, hydroxyethyl cellulose, methylcellulose, carbomer, gelatin, xanthan gum, hyaluronic acid, modified starch, sodium polyacrylate, polyvinyl alcohol, Polyethylene Glycol and polyvidone；Wetting agent can be selected from least one in glycerol, propylene glycol, mannitol butanediol and sorbitol.After adding wetting agent and thickening agent, in addition to strengthening the moisture-keeping function of gel, the most preferable plasticization so that gel coating on wound after skinfeel more soft, and the tight sense of wound will not be produced after gel moisture evaporates, comfortableness is good.
Additionally, the medical recombination chitosan gel of the present invention can also include pH adjusting agent, wherein, the usage amount of pH adjusting agent be the pH value that can adjust medical recombination chitosan gel to 2～11, thus reduce gel dressing and zest during Wound contact.Wherein, pH adjusting agent can be acid or alkali, acid can be selected from least one in hydrochloric acid, acetic acid, sulphuric acid, boric acid, lactic acid, citric acid, tartaric acid, acetic acid and malic acid, and alkali can be selected from least one in sodium hydroxide, sodium carbonate, sodium citrate and triethanolamine.
According to the present invention, the type of service of described medical recombination chitosan gel includes amorphous gel, lamellar gel and spray form gel, can think amorphous gel, lamellar gel or spray form gel.Wherein, preferably amorphous gel, it can be applied not only to epidermal wound, applies also for deep wounds, cave type wound etc., the healing of can preferably fit wound and beneficially wound.Certainly, lamellar gel and spray form gel also have moisture-keeping function clearly, using the teaching of the invention it is possible to provide Moist healing environment and autolyzed debridement effect.And, the medical recombination chitosan gel of the present invention is applicable to acute otch and has the pain chronic wound of low moderate transudate, i.e. it is not only suitable for acute incision, it is also applied for the pain chronic wound of low moderate transudate, such as all kinds of decubital ulcers, vascular lesions ulcer, osteomyelitis, sinus tract etc., but the invention is not restricted to this.
Correspondingly, in order to prepare the medical recombination chitosan gel of multi-form, different preparation technologies can be mated, gel dressing preparation technology commonly used in the art can be used in the present invention to prepare.
Such as, when preparing amorphous gel, first the chitosan of recipe quantity and adjuvant can be dissolved in purified water and be stirred continuously until under optimum conditions and swelling uniformly obtain gel, again the analgesic of recipe quantity added in described gel and stir, utilize afterwards pH adjusting agent regulation product pH value to preset range, by gained gel subpackage, sterilizing, thus obtaining the product amorphous gel.
The most such as; when preparing lamellar gel; first the chitosan family macromolecule material of recipe quantity and adjuvant can be dissolved in purified water and be stirred continuously until under optimum conditions and swelling uniformly obtain gel; again the analgesic of recipe quantity added in described gel and stir, standing and defoaming; utilize pH adjusting agent regulation product pH value to preset range afterwards; by the sialorrhea molding on back lining materials of gained gel, drying and forming-film, combination protecting film, cutting, subpackage, sterilizing, obtain lamellar gel.
The most such as, when preparing spray form gel, first the analgesic of recipe quantity can be dissolved in purified water, and add adjuvant until dissolving, chitosan family macromolecule material is added after mixing, being stirred continuously until formation gel under optimum conditions, utilize pH adjusting agent regulation product pH value to preset range and to add purified water to full dose afterwards, after sterilizing, subpackage i.e. obtains spray form gel；First the chitosan family macromolecule material of recipe quantity and adjuvant can also be dissolved in purified water and be stirred continuously until under optimum conditions and swelling uniformly obtain gel, again the analgesic of recipe quantity is added to described gel and mix homogeneously, utilizing pH adjusting agent regulation product pH value to preset range and to add purified water to full dose afterwards, after standing and defoaming, sterilizing, subpackage i.e. obtains spray form gel.
It should be understood that; above-mentioned embodiment and the example below that the present invention describes in detail are merely to illustrate the present invention rather than limit the scope of the present invention, and some nonessential improvement and adjustment that those skilled in the art makes according to the foregoing of the present invention belong to protection scope of the present invention.The parameter etc. that following example is concrete is the most only that an example in OK range, i.e. those skilled in the art can be selected in the range of being done suitably by explanation herein, and does not really wants to be defined in the concrete numerical value of hereafter example.
The medical recombination chitosan gel to the present invention below in conjunction with embodiment with analgesic activity is described further.
Embodiment 1:
The prescription of the medical recombination chitosan gel amorphous gel containing analgesic is:
Preparation method: (1) weighs the glacial acetic acid of recipe quantity, adds purified water and is configured to the glacial acetic acid solution of 1%, owing to chitosan is only capable of being dissolved in weak acid, so utilizing pH adjusting agent acetic acid to be configured to glacial acetic acid solution to dissolve chitosan；(2) by chitosan, hypromellose and glycerol, join in the glacial acetic acid of above-mentioned 1%, place swelling overnight；(3) lidocaine hydrochloride is dissolved by appropriate purified water, join in the gel that step (2) is formed, be uniformly mixed；(4) with sodium hydrate aqueous solution, the pH value of gel is adjusted to 4～7, supplies the purified water of surplus, sterilizing, packaging, obtain medical recombination chitosan gel.
Prepared gel is applicable to acute otch (such as: all kinds of operative incisions, little debridement surgical, little skin injury and wiping are dampened) and early stage and has the pain chronic wound of low moderate transudate, can play analgesic and act on while providing Moist healing environment, suppression scar hyperplasia, generation physical isolation, autolyzed debridement.
Embodiment 2:
The prescription of the medical recombination chitosan gel amorphous gel containing analgesic is:
Preparation method: (1) weighs recipe quantity carboxymethyl chitosan, sodium carboxymethyl cellulose and glycerol, joins in appropriate purified water, stirring mixing, stands overnight；(2) lignocaine and the prilocaine that weigh recipe quantity join in the gel that step (1) is formed, and are uniformly mixed；(3) with hydrochloric acid/sodium hydroxide, the pH value of gel is adjusted to 7～10, supplies purified water, standing and defoaming, sterilizing, pack and i.e. obtain medical recombination chitosan gel.
Prepared gel is applicable to acute otch (such as: all kinds of operative incisions, little debridement surgical, little skin injury and wiping are dampened) and early stage and has the pain chronic wound of low moderate transudate, can play analgesic and act on while providing Moist healing environment, suppression scar hyperplasia, generation physical isolation, autolyzed debridement.
Embodiment 3:
The prescription of the medical recombination chitosan gel amorphous gel containing analgesic is:
Preparation method: (1), by the carboxymethyl chitosan of recipe quantity, sodium alginate and glycerol, joins in purified water, place swelling overnight；(2) lidocaine hydrochloride is dissolved by appropriate purified water, join in the gel that step (1) is formed, be uniformly mixed；(3) with sodium hydroxide/hydrochloric acid, the pH value of gel is adjusted to 7～9, supplies the purified water of surplus, sterilizing, pack and i.e. obtain medical recombination chitosan gel.
Prepared gel is applicable to acute otch (such as: all kinds of operative incisions, little debridement surgical, little skin injury and wiping are dampened) early stage and has the pain chronic wound of low moderate transudate, can play analgesic and act on while providing Moist healing environment, suppression scar hyperplasia, generation physical isolation, autolyzed debridement.
Embodiment 4:
The prescription of the medical recombination chitosan gel spray shape gel containing analgesic is:
Preparation method: (1) weighs recipe quantity carboxymethyl chitosan, polyvinyl alcohol and glycerol, joins in appropriate purified water, stirring mixing, stands overnight；(2) the lidocaine hydrochloride suitable quantity of water weighing recipe quantity is dissolved, and joins in the gel that step (1) is formed, is uniformly mixed；(3) with hydrochloric acid/sodium hydroxide, the pH value of gel is adjusted to 4～7, supplies purified water, standing and defoaming, sterilizing, pack and i.e. obtain medical recombination chitosan gel.
Prepared gel is applicable to acute otch (such as: all kinds of operative incisions, little debridement surgical, little skin injury and wiping are dampened) and early stage and has the pain chronic wound of low moderate transudate.Directly liquid dressing is sprayed on wound during use, it is to avoid the misery of patient when smearing, also can alleviate wound pain simultaneously.
Embodiment 5:
The prescription of the medical recombination chitosan gel spray shape gel containing analgesic is:
Preparation method: (1) weighs the glacial acetic acid of recipe quantity, adds purified water and is configured to glacial acetic acid aqueous solution, owing to chitosan is only capable of being dissolved in weak acid, so utilizing pH adjusting agent acetic acid to be configured to glacial acetic acid solution to dissolve chitosan；(2) weigh recipe quantity chitosan and glycerol, join in (1) gained solution, stirring mixing, stand overnight；(3) lidocaine hydrochloride weighing recipe quantity joins in the gel that (2) are formed, and is uniformly mixed；(4) purified water is supplied to full dose, standing and defoaming, sterilizing, to pack and i.e. obtain medical recombination chitosan gel, gained pH of latex gel is between 4～7.
Prepared gel is applicable to acute otch (such as: all kinds of operative incisions, little debridement surgical, little skin injury and wiping are dampened) and early stage and has the pain chronic wound of low moderate transudate.Directly gel dressing is sprayed on wound during use, it is to avoid the misery of patient when smearing, also can alleviate infection risk and certain antibacterial action can be played simultaneously.
Embodiment 6:
The prescription of the medical recombination chitosan gel lamellar gel containing analgesic is:
Preparation method: (1) weighs the chitosan quaternary ammonium salt of recipe quantity, hydroxyethyl cellulose and propylene glycol and is placed in appropriate purified water, stirring mixing, stand overnight；(2) the Ropivacaine HCL suitable quantity of water weighing recipe quantity is dissolved, and joins in the gel that step (1) is formed, is uniformly mixed；(3) with sodium hydroxide or hydrochloric acid, the pH value of gel is adjusted to 5～8, standing and defoaming.(4) by the sialorrhea molding on back lining materials of gained gel, drying and forming-film, combines protecting film, cuts, packs, sterilizing, obtain medical recombination chitosan gel.
Prepared gel is applicable to acute otch (such as: all kinds of operative incisions, little debridement surgical, little skin injury and wiping are dampened) and early stage and has the pain chronic wound of low moderate transudate.During use, dressing is affixed on wound, can be that wound provides the healing of Moist healing environment, assist wound to play analgesic activity simultaneously.Gel film is transparent simultaneously, it is simple to observe the healing state of wound.
Embodiment 7:
The prescription of the medical recombination chitosan gel lamellar gel containing analgesic is:
Preparation technology is as follows: (1) weighs the hydroxypropyl chitosan of recipe quantity, hydroxypropyl cellulose, Polyethylene Glycol and glycerol and is placed in appropriate purified water, stirring mixing, stands overnight；(2) the lidocaine hydrochloride suitable quantity of water weighing recipe quantity is dissolved, and joins in the gel that step (1) is formed, is uniformly mixed；(3) with sodium hydroxide or hydrochloric acid, the pH value of gel is adjusted to 4～6, standing and defoaming；(4) by the sialorrhea molding on back lining materials of gained gel, drying and forming-film, combines protecting film, cuts, packs, sterilizing, thus obtaining the product medical recombination chitosan gel.
Prepared gel is applicable to acute otch (such as: all kinds of operative incisions, little debridement surgical, little skin injury and wiping are dampened) and early stage and has the pain chronic wound of low moderate transudate.During use, dressing is affixed on wound, can be that wound provides the healing of Moist healing environment, assist wound to play analgesic activity simultaneously.Gel film is transparent simultaneously, it is simple to observe the healing state of wound.
Embodiment 8:
The prescription of the medical amorphous gel of recombination chitosan gel containing analgesic is:
Preparation technology is as follows: (1) weighs the chitosan hydrochlorate of recipe quantity, gelatin and propylene glycol and is placed in appropriate purified water, stirring mixing, stands overnight；(2) the bupivacaine hydrochloride suitable quantity of water weighing recipe quantity is dissolved, and joins in the gel that step (1) is formed, is uniformly mixed；(3) with sodium hydroxide/hydrochloric acid, the pH value of gel is adjusted to 4～7, supplies the purified water of surplus, standing and defoaming, sterilizing, pack and i.e. obtain medical recombination chitosan gel.
Prepared gel is applicable to acute otch (such as: all kinds of operative incisions, little debridement surgical, little skin injury and wiping are dampened) and early stage and has the pain chronic wound of low moderate transudate.During use, dressing is applied in wound, can be that wound provides the healing of Moist healing environment, assist wound to play analgesic activity simultaneously.Gel film is transparent simultaneously, it is simple to observe the healing state of wound.
In sum, the present invention provides for skin and mucosa injury patient a kind of to be had pain relieving, stops blooding, provides Moist healing environment, autolyzed debridement, controls scar hyperplasia and the gel dressing of physical isolation effect, and analgesic contained therein can effectively play analgesic effect.
The invention is not limited in aforesaid detailed description of the invention.The present invention expands to any new feature disclosed in this manual or any new combination, and the arbitrary new method that discloses or the step of process or any new combination.
Claims (10)
1. the medical recombination chitosan gel containing analgesic, it is characterised in that in parts by weight,
Described medical recombination chitosan gel includes following components: 0.5～10 part of chitosan family macromolecule material, 0.5～7
Part analgesic, 0～10 part of thickening agent, 1～25 part of wetting agent and 48～98 parts of purified water.
Medical recombination chitosan gel containing analgesic the most according to claim 1, its feature
Being, described medical recombination chitosan gel includes following components: 1.5～6 parts of chitosan family macromolecule materials,
1～5 part of analgesic, 0～5 part of thickening agent, 4～15 parts of wetting agents and 69～93.5 parts of purified water.
3. according to described in claim 1 or 2 containing the medical recombination chitosan gel of analgesic, its
Being characterised by, described medical recombination chitosan gel also includes pH adjusting agent, wherein, described pH regulator
The usage amount of agent is that the pH value that can adjust described medical recombination chitosan gel is to 2～11.
Medical recombination chitosan gel containing analgesic the most according to claim 1 and 2, its
It is characterised by, described chitosan family macromolecule material deriving selected from chitosan, the salt of chitosan and chitosan
At least one in thing；The derivant of described chitosan is selected from carboxymethyl chitosan, isobutyl-chitosan, hydroxyl
At least one in propyl group chitosan and hyaluronic acid-like chitosan；The salt of described chitosan is selected from chitosan season
Ammonium salt, chitosan hydrochlorate, chitosan lactate, chitosan acetate, chitosan tartarate, shell are poly-
Sugar sulfate, glutamate, Chitosan citrate., chitosan succinate and chitosan acetyl
At least one in salicylate；The molecular weight of described chitosan family macromolecule material is 1000～1000000.
Medical recombination chitosan gel containing analgesic the most according to claim 1 and 2, its
Being characterised by, described analgesic is dispersed or dissolved in described medical recombination chitosan gel, wherein, and institute
State analgesic and be selected from lignocaine or its salt, prilocaine or its salt, bupivacaine or its salt and sieve piperazine card
At least one in cause or its salt.
Medical recombination chitosan gel containing analgesic the most according to claim 1 and 2, its
Be characterised by, described thickening agent selected from starch, alginic acid and salt thereof, arabic gum, tragakanta, agar,
Cellulose, sodium carboxymethyl cellulose, hydroxypropyl cellulose, hypromellose, hydroxyethyl cellulose, first
Base cellulose, carbomer, gelatin, xanthan gum, hyaluronic acid, modified starch, sodium polyacrylate, poly-second
At least one in enol, Polyethylene Glycol and polyvidone.
Medical recombination chitosan gel containing analgesic the most according to claim 1 and 2, its
Being characterised by, described wetting agent is selected from glycerol, propylene glycol, mannitol, butanediol and sorbitol at least
A kind of.
Medical recombination chitosan gel containing analgesic the most according to claim 3, its feature
Being, described pH adjusting agent is acid or alkali, and wherein, acid is selected from hydrochloric acid, acetic acid, sulphuric acid, boric acid, breast
At least one in acid, citric acid, tartaric acid, acetic acid and malic acid, alkali selected from sodium hydroxide, sodium carbonate,
At least one in sodium citrate and triethanolamine.
Medical recombination chitosan gel containing analgesic the most according to claim 1 and 2, its
Being characterised by, the type of service of described medical recombination chitosan gel is amorphous gel, lamellar gel or spray
Vaporific gel.
Medical recombination chitosan gel containing analgesic the most according to claim 1 and 2, its
Being characterised by, described medical recombination chitosan gel is applicable to acute otch and has the pain of low moderate transudate
Chronic wound.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610390055.7A CN105903068A (en) | 2016-06-02 | 2016-06-02 | Medical composite chitosan gel containing analgesic drug |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610390055.7A CN105903068A (en) | 2016-06-02 | 2016-06-02 | Medical composite chitosan gel containing analgesic drug |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105903068A true CN105903068A (en) | 2016-08-31 |
Family
ID=56743222
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610390055.7A Pending CN105903068A (en) | 2016-06-02 | 2016-06-02 | Medical composite chitosan gel containing analgesic drug |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105903068A (en) |
Cited By (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106581740A (en) * | 2016-12-09 | 2017-04-26 | 苏州纳贝通环境科技有限公司 | Hemostatic and antibacterial medical dressing and preparation method thereof |
| CN106937942A (en) * | 2017-03-30 | 2017-07-11 | 广东泰宝医疗科技股份有限公司 | A kind of medical skin wound analgesia gel and preparation method thereof |
| CN106943340A (en) * | 2017-04-28 | 2017-07-14 | 北京茗泽中和药物研究有限公司 | A kind of lidocaine hydrochloride jelly |
| CN107583101A (en) * | 2017-09-27 | 2018-01-16 | 广州润虹医药科技股份有限公司 | A kind of biological membrane preparations for promoting wound healing and preparation method thereof |
| CN108159508A (en) * | 2018-01-03 | 2018-06-15 | 东南大学 | A kind of preparation method of anti-adhesion medical hydrogel material |
| CN108295301A (en) * | 2018-04-23 | 2018-07-20 | 朱东洋 | A kind of liquid adhesive bandage and preparation method thereof |
| CN109106978A (en) * | 2018-08-29 | 2019-01-01 | 希瑞干细胞科技有限公司 | A kind of human skin fibroblasts culture supernatant dressing and preparation method thereof |
| CN109432490A (en) * | 2018-10-17 | 2019-03-08 | 苏州汇涵医用科技发展有限公司 | A kind of transparent aquagel and its preparation method and application |
| CN110507845A (en) * | 2019-09-25 | 2019-11-29 | 广州沁瀚生物科技有限公司 | Biological composite ventilating dressing and preparation method thereof |
| CN111166932A (en) * | 2020-02-29 | 2020-05-19 | 海南妙音春制药有限公司 | Liquid wound spray dressing and preparation method thereof |
| CN111330011A (en) * | 2020-04-16 | 2020-06-26 | 济南秦鲁药业科技有限公司 | Chitosan vaginal gel |
| WO2020211787A1 (en) * | 2019-04-15 | 2020-10-22 | 湖州依诺唯新药物制剂有限公司 | Pharmaceutical preparation, system comprising same, preparation method therefor and application thereof |
| CN111991612A (en) * | 2020-08-29 | 2020-11-27 | 山东百多安医疗器械股份有限公司 | Preparation method of liquid dressing with analgesic and antibacterial functions |
| CN113209006A (en) * | 2021-05-11 | 2021-08-06 | 南京先宇科技有限公司 | Compound modified chitin gel preparation and preparation method thereof |
| CN113476489A (en) * | 2020-12-31 | 2021-10-08 | 成都中医药大学 | Ligusticum wallichii volatile oil plaster for treating dysmenorrhea as well as preparation method and application thereof |
| CN114129507A (en) * | 2021-07-13 | 2022-03-04 | 浙江仙琚制药股份有限公司 | Progesterone gel composition and preparation method thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101049514A (en) * | 2007-05-11 | 2007-10-10 | 东华大学 | Antibacterial anti hemorrhagic antalgic dressing of medical use, preparation and application |
| CN101278896A (en) * | 2008-05-23 | 2008-10-08 | 山东赛克赛斯药业科技有限公司 | Chitosan nano silver gel agent and uses thereof |
| CN102755662A (en) * | 2012-07-25 | 2012-10-31 | 福州乾正药业有限公司 | Medical gel film prepared by compounding chitosan and preparation method of same |
-
2016
- 2016-06-02 CN CN201610390055.7A patent/CN105903068A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101049514A (en) * | 2007-05-11 | 2007-10-10 | 东华大学 | Antibacterial anti hemorrhagic antalgic dressing of medical use, preparation and application |
| CN101278896A (en) * | 2008-05-23 | 2008-10-08 | 山东赛克赛斯药业科技有限公司 | Chitosan nano silver gel agent and uses thereof |
| CN102755662A (en) * | 2012-07-25 | 2012-10-31 | 福州乾正药业有限公司 | Medical gel film prepared by compounding chitosan and preparation method of same |
Cited By (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106581740A (en) * | 2016-12-09 | 2017-04-26 | 苏州纳贝通环境科技有限公司 | Hemostatic and antibacterial medical dressing and preparation method thereof |
| CN106937942A (en) * | 2017-03-30 | 2017-07-11 | 广东泰宝医疗科技股份有限公司 | A kind of medical skin wound analgesia gel and preparation method thereof |
| CN106943340A (en) * | 2017-04-28 | 2017-07-14 | 北京茗泽中和药物研究有限公司 | A kind of lidocaine hydrochloride jelly |
| CN107583101A (en) * | 2017-09-27 | 2018-01-16 | 广州润虹医药科技股份有限公司 | A kind of biological membrane preparations for promoting wound healing and preparation method thereof |
| CN108159508A (en) * | 2018-01-03 | 2018-06-15 | 东南大学 | A kind of preparation method of anti-adhesion medical hydrogel material |
| CN108295301A (en) * | 2018-04-23 | 2018-07-20 | 朱东洋 | A kind of liquid adhesive bandage and preparation method thereof |
| CN109106978A (en) * | 2018-08-29 | 2019-01-01 | 希瑞干细胞科技有限公司 | A kind of human skin fibroblasts culture supernatant dressing and preparation method thereof |
| CN109432490A (en) * | 2018-10-17 | 2019-03-08 | 苏州汇涵医用科技发展有限公司 | A kind of transparent aquagel and its preparation method and application |
| WO2020211787A1 (en) * | 2019-04-15 | 2020-10-22 | 湖州依诺唯新药物制剂有限公司 | Pharmaceutical preparation, system comprising same, preparation method therefor and application thereof |
| CN110507845A (en) * | 2019-09-25 | 2019-11-29 | 广州沁瀚生物科技有限公司 | Biological composite ventilating dressing and preparation method thereof |
| CN111166932A (en) * | 2020-02-29 | 2020-05-19 | 海南妙音春制药有限公司 | Liquid wound spray dressing and preparation method thereof |
| CN111166932B (en) * | 2020-02-29 | 2021-01-26 | 海南妙音春制药有限公司 | Liquid wound spray dressing and preparation method thereof |
| CN111330011A (en) * | 2020-04-16 | 2020-06-26 | 济南秦鲁药业科技有限公司 | Chitosan vaginal gel |
| CN111991612A (en) * | 2020-08-29 | 2020-11-27 | 山东百多安医疗器械股份有限公司 | Preparation method of liquid dressing with analgesic and antibacterial functions |
| CN113476489A (en) * | 2020-12-31 | 2021-10-08 | 成都中医药大学 | Ligusticum wallichii volatile oil plaster for treating dysmenorrhea as well as preparation method and application thereof |
| CN113476489B (en) * | 2020-12-31 | 2022-10-11 | 成都中医药大学 | Ligusticum wallichii volatile oil plaster for treating dysmenorrhea as well as preparation method and application thereof |
| CN113209006A (en) * | 2021-05-11 | 2021-08-06 | 南京先宇科技有限公司 | Compound modified chitin gel preparation and preparation method thereof |
| CN114129507A (en) * | 2021-07-13 | 2022-03-04 | 浙江仙琚制药股份有限公司 | Progesterone gel composition and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105903068A (en) | Medical composite chitosan gel containing analgesic drug | |
| CN106039394A (en) | Medical composite chitosan gel containing antibacterial drug | |
| CN103495199B (en) | A kind of laser for the treatment of is burnt and the hydrogel wound dressing and preparation method thereof of burn and scald | |
| CN104257639B (en) | A kind of liniment for Wound treating and preparation method thereof | |
| CN106075556A (en) | Containing the medical recombination chitosan gel promoting wound healing medicine | |
| EP1863469B1 (en) | A topical analgesic composition | |
| CN102058900B (en) | Waterproof liquid bandage for wound surface protection and preparation method thereof | |
| EP2292257A2 (en) | Compositions and methods for dermatological wound healing | |
| CA2409076A1 (en) | Composition and method for growing, protecting, and healing tissues and cells | |
| EP1830895A2 (en) | Agents for controlling biological fluids and methods of use thereof | |
| CN105816911A (en) | Repairing gel containing growth factors and preparation method of repairing gel | |
| JPH06104624B2 (en) | Transdermal agent | |
| CN102846655A (en) | Formulation and preparation method of antibacterial spray | |
| US20230093154A1 (en) | Topical formulations and treatments | |
| CN108159024A (en) | A kind of sustained release pad pasting for treating canker sore and preparation method thereof | |
| RU2649790C1 (en) | Antiseptic composition containing unithiol and dimethylsulfoxide, application of such a composition and method of wound treatment with the use of it | |
| WO2006094064A2 (en) | Method of reducing scars with vitamin d | |
| Wong et al. | Scar-free healing of wounds resulting commonly from domestic accidents | |
| CN110251716A (en) | A kind of wound care gel dressing and preparation method thereof | |
| CN105963281A (en) | Chitin scar-restraint gel coating as well as preparation method and application thereof | |
| CN115025070B (en) | Quick self-film-forming anti-infection analgesic spray and preparation method and application thereof | |
| RU2559087C1 (en) | Composition for treating burns | |
| CN202105203U (en) | Sticking membrane for dermatosis and ulcer wound surface | |
| TWI792983B (en) | Use of adenine for the manufacture of a medicament for treating diabetic ulcer | |
| WO2007094413A1 (en) | Medicinal composition for transdermal administration |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20160831 |
|
| WD01 | Invention patent application deemed withdrawn after publication |